A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents

DOI10.1111/J.1541-0420.2008.01119.XMaRDI QIDQ3183236zbMATH OpenOpenAlexWikidataFDO

Authors Guosheng Yin, Ying Yuan

Publication date 19 October 2009

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.1541-0420.2008.01119.x

zbMATH Keywords

tablesmaximum tolerated doseBayesian estimationGibbs samplingsynergyadaptive designtoxicityphase I trialcombining drugs

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Contingency tables (62H17)

Recommendations

• Dose-finding with two agents in phase I oncology trials
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Bayesian dose finding for combined drugs with discrete and continuous doses
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response

Cites work

• A Curve‐Free Method for Phase I Clinical Trials
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies
• A Random Walk Rule for Phase I Clinical Trials
• Adaptive Rejection Metropolis Sampling within Gibbs Sampling
• Bayesian optimal designs for phase I clinical trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Designs for Single- or Multiple-Agent Phase I Trials
• Dose finding in drug development.
• Dose finding using the biased coin up-and-down design and isotonic regression
• Dose-finding with two agents in phase I oncology trials
• Experimental Design for Joint Action
• General Models for the Joint Action of Mixtures of Drugs
• Statistical Methods for Dose‐Finding Experiments
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Two‐Dimensional Dose Finding in Discrete Dose Space

Cited in

(13)

• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• Continual reassessment method for partial ordering
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
• Adaptive clinical trial designs for phase I cancer studies
• Dose-finding with two agents in phase I oncology trials
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
• Application of gamma process to two-agent combinations with delayed toxicity

This page was built for publication: A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3183236)